CIR Expert Panel To Prioritize Cannabidiol Review In 2024 At FDA’s Request

 
• By Lauren Nardella

Cosmetic Ingredient Review’s independent experts note that CBD use in cosmetic products has increased since FDA first asked them to prioritize its review in 2020.

Conceptual image of CBD legalization and use.

Cosmetic Ingredient Review’s Expert Panel For Cosmetic Ingredient Safety will prioritize cannabidiol for review in 2024 at the US Food and Drug Administration’s request.

The agency initially asked the panel to add CBD to its list of 2020 priorities, but CBD had no reported...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Ingredients & Safety

More from HBW Insight